Aspect Biosystems
Vancouver, United States· Est.
Is this your company? Claim your profile to update info and connect with investors.
Claim profilePrivate Company
Total funding raised: $115M
Overview
Creating 3D bioprinted human tissue therapeutics for disease treatment.
Regenerative MedicineMetabolic Disease
Technology Platform
A proprietary microfluidic 3D bioprinting platform that precisely assembles living cells and biomaterials to create functional human tissues for therapeutic implantation.
Funding History
1Total raised:$115M
Venture$115M
Opportunities
Pioneering a new modality of medicine—implantable, lab-grown human tissues—to address conditions with limited treatment options, such as type 1 diabetes.
Risk Factors
Faces significant translational challenges in achieving vascularization, long-term engraftment, and functional efficacy of complex bioprinted tissues in humans.
Competitive Landscape
Operates in the emerging field of 3D bioprinting for therapeutics, competing with other tissue engineering approaches but with a differentiated microfluidic fabrication technology.